TRYP Therapeutics: Tryp Therapeutics Completes Initial Public Offering
Tryp or the
Offering ) of units (the
Units ). A total of 20,010,000 Units were sold, including 2,610,000 Units following the exercise in full by the Agent (as defined herein) of its over-allotment option, at a price of $0.25 per Unit for aggregate gross proceeds of $5,002,500.
Each Unit consists of one common share in the capital of the Company (each a
Common Share )
Warrant ). Each Warrant is exercisable into one Common Share (each, a
Warrant Share ) at an exercise price of $0.50 per Warrant Share at any time prior to 5:00 p.m. (Vancouver time) on December 16, 2021, subject to acceleration in certain events.
TRYP Therapeutics: Tryp Therapeutics Files Final Prospectus and Announces Initial Public Offering
Tryp or the
Company ) is pleased to announce that it has obtained a receipt for its final prospectus, which was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario on December 8, 2020 in connection with the initial public offering (the
Offering ) of 17,400,000 units of the Company (the
Units ) at a price of $0.25 per Unit. The aggregate gross proceeds of the Offering will be $4,350,000.
Each Unit consists of one common share in the capital of the Company (each a
Common Share )
Warrant ). Each Warrant is exercisable into one Common Share (each, a